Research Analysts Set Expectations for ACHV Q3 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Stock analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for shares of Achieve Life Sciences in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will earn ($0.22) per share for the quarter, up from their prior estimate of ($0.23). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.54) EPS and FY2027 earnings at ($0.79) EPS.

A number of other research analysts also recently commented on ACHV. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $18.00 price target on shares of Achieve Life Sciences in a report on Wednesday. Canaccord Genuity Group set a $13.00 price objective on Achieve Life Sciences and gave the stock a “buy” rating in a research note on Monday, April 20th. Weiss Ratings upgraded Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. UBS Group restated a “buy” rating on shares of Achieve Life Sciences in a research report on Wednesday. Finally, Morgan Stanley initiated coverage on Achieve Life Sciences in a research note on Thursday. They issued an “overweight” rating and a $13.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $15.00.

Achieve Life Sciences Stock Performance

Achieve Life Sciences stock opened at $6.69 on Thursday. The company’s 50-day moving average price is $6.03 and its 200-day moving average price is $4.90. Achieve Life Sciences has a twelve month low of $2.45 and a twelve month high of $7.11. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.87. The company has a market cap of $686.80 million, a PE ratio of -4.32 and a beta of 2.24.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.64).

Institutional Investors Weigh In On Achieve Life Sciences

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Achieve Life Sciences in the 2nd quarter worth about $34,426,000. Franklin Resources Inc. grew its stake in shares of Achieve Life Sciences by 18,747.4% during the fourth quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company’s stock valued at $21,715,000 after buying an additional 4,346,011 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in shares of Achieve Life Sciences during the second quarter valued at approximately $2,652,000. Millennium Management LLC raised its holdings in shares of Achieve Life Sciences by 472.3% in the fourth quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock worth $6,755,000 after buying an additional 1,121,614 shares during the period. Finally, Pathstone Holdings LLC purchased a new stake in shares of Achieve Life Sciences in the third quarter worth approximately $1,581,000. Institutional investors own 33.52% of the company’s stock.

Key Headlines Impacting Achieve Life Sciences

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $12 price target, well above recent trading levels. Its estimates still project Achieve becoming profitable, with positive EPS forecast for 2028 through 2030. HC Wainwright analyst estimates
• Positive Sentiment: Achieve Life Sciences’ shares have nearly tripled over the past year, reflecting investor optimism about its pipeline and the potential commercial opportunity if the company can achieve profitability. Achieve Life Sciences stock has nearly tripled in the last year
• Neutral Sentiment: Reported short interest was listed at zero shares, implying no meaningful short-position data or short-squeeze catalyst in the latest report.
• Negative Sentiment: The company reported a second-quarter loss of $0.80 per share, substantially worse than the consensus loss estimate of $0.16. The miss reinforces concerns that Achieve remains well short of profitability. Achieve Life Sciences Reports Second Quarter 2026 Financial Results
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for 2028, 2029 and 2030 to $0.23, $0.97 and $1.47, respectively, from $0.24, $1.00 and $1.51. Although the firm remains bullish, the downward revisions suggest a somewhat slower profit ramp.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.